CytoKi Pharma


CytoKi closes $45M series A to harness IL-22 signaling for epithelial repair.

CytoKi Pharma today announced a $45 million series A financing led by existing investor Lundbeckfonden Emerge (Denmark) together with Seventure Partners (France), +ND Capital (Switzerland) and Ysios Capital (Spain). The series A will support the development of its lead program (lipidated IL-22) through clinical proof of concept in Inflammatory Bowel Disease and explore expansion in additional pathologies related to epithelial tissue injury.

Read full press release

Lundbeckfonden takes former Novo-boss’ biotech baby under its wing.

A new drug at Novo Nordisk’s lab sparked such big interest for Rasmus Jørgensen that he decided to leave the diabetes giant and build his own biotech firm from it. Now Lundbeckfonden will help him find the money.

Read article

About Us

CytoKi Pharma is a pre-clinical biotechnology company with focus on serious diseases caused by epithelial injury having an unmet medical need.


CytoKi Pharma
Tuborg Boulevard 12
DK-2900 Hellerup